We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ARTES Announces a Strategic Collaboration Deal for Vaccine Development
News

ARTES Announces a Strategic Collaboration Deal for Vaccine Development

ARTES Announces a Strategic Collaboration Deal for Vaccine Development
News

ARTES Announces a Strategic Collaboration Deal for Vaccine Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ARTES Announces a Strategic Collaboration Deal for Vaccine Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell.

Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.

Aim of the long-term research cooperation is a new-product development on the basis of ARTES’ virus like particle (VLP) and the well-established Hansenula polymorpha expression system fitting to Crucell’s vaccine portfolio.

The Hansenula system is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns.

In combination, the unique yeast based VLP approach builds a new and very economical approach to low-cost mass production of safe and effective vaccines.

Under the terms of the long-term research collaboration ARTES is responsible for delivery of the production cell lines and processes to Crucell.

Advertisement